208 related articles for article (PubMed ID: 25976473)
1. Thalassemia major between liver and heart: Where we are now.
Dessì C; Leoni G; Moi P; Danjou F; Follesa I; Foschini ML; Morittu M; Zappu A; Defraia E; Bina P; Cunico A; Civolani A; Podda RA; Origa R
Blood Cells Mol Dis; 2015 Jun; 55(1):82-8. PubMed ID: 25976473
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
3. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
4. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
5. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
7. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
[TBL] [Abstract][Full Text] [Related]
8. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
[TBL] [Abstract][Full Text] [Related]
9. Extramedullary hematopoiesis is associated with lower cardiac iron loading in chronically transfused thalassemia patients.
Ricchi P; Meloni A; Spasiano A; Neri MG; Gamberini MR; Cuccia L; Caruso V; Gerardi C; D'Ascola DG; Rosso R; Campisi S; Rizzo M; Terrazzino F; Vangosa AB; Chiodi E; Missere M; Mangione M; Positano V; Pepe A
Am J Hematol; 2015 Nov; 90(11):1008-12. PubMed ID: 26228763
[TBL] [Abstract][Full Text] [Related]
10. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Huang YC; Chang JS; Wu KH; Peng CT
Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
12. Correlation of NT-proBNP levels and cardiac iron concentration in patients with transfusion-dependent thalassemia major.
Delaporta P; Kattamis A; Apostolakou F; Boiu S; Bartzeliotou A; Tsoukas E; Papassotiriou I
Blood Cells Mol Dis; 2013 Jan; 50(1):20-4. PubMed ID: 23017692
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.
Berdoukas V; Chouliaras G; Moraitis P; Zannikos K; Berdoussi E; Ladis V
J Cardiovasc Magn Reson; 2009 Jun; 11(1):20. PubMed ID: 19558722
[TBL] [Abstract][Full Text] [Related]
15. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Kolnagou A; Natsiopoulos K; Kleanthous M; Ioannou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
[TBL] [Abstract][Full Text] [Related]
16. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C in patients with β-thalassemia major. A single-centre experience.
Triantos C; Kourakli A; Kalafateli M; Giannakopoulou D; Koukias N; Thomopoulos K; Lampropoulou P; Bartzavali C; Fragopanagou H; Kagadis GC; Christofidou M; Tsamandas A; Nikolopoulou V; Karakantza M; Labropoulou-Karatza C
Ann Hematol; 2013 Jun; 92(6):739-46. PubMed ID: 23412560
[TBL] [Abstract][Full Text] [Related]
18. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
[TBL] [Abstract][Full Text] [Related]
19. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
[TBL] [Abstract][Full Text] [Related]
20. Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy.
Berdoukas V; Bohane T; Tobias V; De Silva K; Fraser I; Aessopos A; Lindeman R
Hematol J; 2005; 5(7):572-8. PubMed ID: 15692602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
